GLAXO — GlaxoSmithKline Pharmaceuticals Balance Sheet
0.000.00%
- IN₹570.36bn
- IN₹544.53bn
- IN₹37.49bn
Annual balance sheet for GlaxoSmithKline Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
R2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 11,372 | 28,309 | 16,541 | 18,568 | 24,981 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,975 | 3,052 | 3,419 | 3,720 | 3,848 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 22,026 | 37,080 | 24,943 | 27,984 | 34,099 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3,554 | 3,254 | 3,151 | 3,107 | 2,839 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 31,146 | 46,333 | 33,266 | 35,566 | 41,081 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 13,546 | 16,984 | 13,264 | 15,249 | 19,052 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 16,364 | 19,703 | 15,853 | 17,790 | 21,568 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 14,783 | 26,630 | 17,413 | 17,776 | 19,513 |
Total Liabilities & Shareholders' Equity | 31,146 | 46,333 | 33,266 | 35,566 | 41,081 |
Total Common Shares Outstanding |